Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > New Co Makefield Therapeutics gains Nanoparticle Tech for Anti-infective, Men's Health Apps

Abstract:
Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery Platform from Albert Einstein College of Medicine

Uses Include Topical Antimicrobial and Erectile Dysfunction Therapies

New Co Makefield Therapeutics gains Nanoparticle Tech for Anti-infective, Men's Health Apps

Newtown, PA | Posted on December 16th, 2009

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform. Makefield Therapeutics is utilizing two different topical formulations of the nitric oxide (NO)-containing nanoparticles in its therapeutic development programs: an antimicrobial for the treatment of drug resistant skin and soft tissue infections; and a topical treatment for Erectile Dysfunction (ED) in men unresponsive or dissatisfied with currently available oral drug treatments.

"Nitric oxide, Science Magazine's 1992 ‘Molecule of the Year,' has been the focus of immense medical and scientific exploration," said Robert Towarnicki, president and chief executive officer of Makefield Therapeutics "Until now, however, the difficulty of conveniently and effectively delivering the gas to targeted tissues has limited the therapeutic application of nitric oxide.

The inventors at Einstein, led by Joel Friedman, MD, PhD, have developed a novel method for storing and delivering nitric oxide in a therapeutically relevant manner, through the use of biodegradable nanoparticles constructed of ‘Generally Recognized as Safe' (GRAS) components. We are very pleased to gain access to this promising drug delivery platform, for which the inventors have already published proof-of-concept in several very high value applications."

Mr. Towarnicki noted that multiple, published peer-reviewed articles have demonstrated in animal models the therapeutic potential of the nitric oxide-containing nanoparticles, both as a broad-spectrum antimicrobial and as a topical treatment for erectile dysfunction. Makefield Therapeutics plans to develop these two lead indications commercially and expand the uses of the technology to address other therapeutic applications where the Hybrid Nanoparticle™ technology platform can be enabling.

####

About Makefield Therapeutics
Makefield Therapeutics, Inc., founded in July 2009, is a privately held therapeutics company with two development programs addressing large market opportunities in anti-infectives and the treatment of erectile dysfunction. Both programs are based on an innovative nanoparticle drug delivery platform with the potential to generate a pipeline of additional novel therapeutics.

About the “Hybrid Nanoparticles™ Technology Platform

Hybrid Nanoparticles™ have for the first time enabled the practical delivery of therapeutic amounts of nitric oxide gas (NO) in a local, controlled, and sustained manner. The platform is also capable of delivering peptides, nucleic acids and traditional small molecule pharmaceuticals, both as single therapeutic entities and in combination treatments as well.

Multiple routes of administration including transdermal/topical, oral, intravenous, intraperitoneal, and instillation are possible utilizing this technology. The delivery system is capable of providing for immediate, pulsatile and sustained controlled drug release both locally and systemically.

The delivery system is biodegradable and utilizes excipients that are Generally Recognized as Safe (GRAS), USP-NF listed or previously utilized in medical applications. All of the components of the drug delivery system are commercially available in pharmaceutical grade and the methods of preparation use well-known pharmaceutical unit operations that easily lend themselves to scale up and manufacture.

For more information, please click here

Contacts:
Robert J. Towarnicki
President and CEO

(215) 321-5713

For Media
Joan Kureczka
Kureczka/Martin Associates
(415) 821 2413

Copyright © Makefield Therapeutics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Products

Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015

DELSEY by Philippe Starck DELSEY Launches New Collection by Philippe Starck February 4th, 2015

NEI introduces NANOMYTE® SuperAi, a Durable Anti-ice Coating December 4th, 2014

Biosenta Inc. Updates New Household Disinfectant Testing Results; It Kills 100% of a Broad Range of Deadly Molds, Fungi, Bacteria, and Viruses, Including Ebola and Enterovirus D68 November 20th, 2014

Nanomedicine

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Announcements

Nanoscale worms provide new route to nano-necklace structures March 29th, 2015

Solving molybdenum disulfide's 'thin' problem: Research team increases material's light emission by twelve times March 29th, 2015

A first glimpse inside a macroscopic quantum state March 28th, 2015

DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015

Nanobiotechnology

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

Dolomite’s microfluidics technology ideal for B cell encapsulation March 24th, 2015

Tiny bio-robot is a germ suited-up with graphene quantum dots March 24th, 2015

TGAC's take on the first portable DNA sequencing 'laboratory': First remote laboratory allows researchers to conduct real-time anaylsis March 19th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE